Comparison of the Effects of Inspiratory Muscle Training and Baduanjin Exercises in Hypertrophic Cardiomyopathy Patients

Recruiting now · Not applicable

Conditions studied: Hypertrophic Cardiomyopathy, Heart Diseases

In brief

The study aims to compare the effects of inspiratory muscle training and Baduanjin exercises on pulmonary function, exercise capacity, and quality of life in patients with hypertrophic cardiomyopathy. By investigating these interventions, the investigators seek to introduce novel approaches that can enhance pulmonary function, exercise capacity, and overall quality of life for these patients. In the study, which will involve three groups-the control group, the inspiratory muscle training (IMT) group, and the Baduanjin group-it was calculated that a total of 51 patients, with 17 in each group (n = 17), should be included. The IMT group will use an inspiratory muscle training device twice a day, every day of the week, for 15 minutes. This training will continue for 8 weeks, with supervision once a week and unsupervised sessions on the other days. The Baduanjin group will participate in a 50-minute exercise program, which includes a 10-minute warm-up, a 30-minute routine of eight separate movements, and a 10-minute cool-down. This will occur three times a week (twice in person and once online) for 8 weeks.

Key facts

Study ID

NCT06490250

Run by

Istanbul University - Cerrahpasa

People needed

51

Starts

2024-10-25

Expected to finish

2025-11-30

Last updated by the study team

2025-06-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Myocardial thickness in any region of the left ventricle is 15 mm or more on echocardiography or cardiac MRI
• Clinically and hemodynamically stable (patients with NYHA Class I and II)
• Patients over 18 years of age
• Patients who provide informed consent

You may not qualify if…

• Acute decompensated heart failure
• Decreased ejection fraction (<40%)
• Unstable angina pectoris
• Significant coronary artery disease (CAD)
• Severe renal dysfunction (estimated glomerular filtration rate <30 mL/min/m²)
• Uncontrolled hypertension (despite medication)
• Severe valve disease (moderate-severe aortic stenosis, advanced mitral regurgitation)
• Severe neurological disorders causing autonomic dysfunction
• Cognitive impairment that prevents communication
• Recent fractures, osteoporosis, presence of tumors, pregnancy, or back and spine problems

Where it is running

• Istanbul University-Cerrahpasa (IUC) Cardiology Institute — Istanbul, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.